Hospitalization Risk from Onglyza Heart Failure Questioned in New Study
The findings of a new study claiming Onglyza does not cause heart failure are in contrast to findings by a panel of FDA experts who want new warnings placed on…
Tag Archives: Januvia
-
-
Summary Judgment Sought in Pancreatic Cancer Lawsuits Over Januvia, Janumet, Byetta, Victoza
A federal judge has been asked to enter summary judgement in failure to warn lawsuits filed over the pancreatic cancer risk with Byetta, Januvia, Janumet and Victoza, arguing that the…
-
Health Problems Linked to Invokana, Farxiga, Onglyza, Nesina in Adverse Event Reports
Some diabetes drugs unexpected linked to heart failure risks, new report finds.
-
Januvia Heart Risks Not Seen in New Study for Diabetes Drug
A new study failed to find links between Januvia and increased cardiovascular risks.
-
Nesina Heart Failure Side Effects Require Warning Update: FDA Panel
An FDA advisory panel has voted to add new label warnings to the diabetes drug Nesina.
-
Onglyza Heart Failure Warnings Should Be Added, FDA Advisors Say
An FDA advisory committee is calling on the agency to add new warning labels to the diabetes drug Onglyza, including warnings of risks of heart failure and death.
-
Onglyza Side Effects Increase Risk of Death, FDA Reviewers Warn
FDA reviewers warn that the diabetes drug Onglyza may increase the risk of death in some patients.
-
Diabetics May Face Increased Risk of Pancreatic Cancer: Study
A new study links blood glucose levels to an increased risk of pancreatic cancer.
-
New Report Highlights FDA Drug Approval System’s Failings, Diabetes Drug Risks
A new report highlights problems with the FDA's drug approval and postmarketing monitoring processes, focusing on the side effects of diabetes drugs like Byetta, Januvia and Victoza.
-
Judge Denies Plaintiff Request for Source Data on Byetta, Januvia Problems
A federal judge has rejected a call for access to source data on adverse event reports tied to some diabetes drugs and pancreatic cancer, saying it would lead to the…
